PreComb Therapeutics AG
PreComb Therapeutics AG is a Swiss biotech company developing proprietary technologies, including 3D cell culture and process automation, to enable evidence-based cancer treatment decisions using patient-derived tumor samples.
Classification
Profile
Funding
Funding details not yet available.
Enables evidence-based cancer treatment decisions by screening patient-derived tumour samples against compounds and combinations to identify actionable oncology therapies.
Oncology researchers and clinicians seeking personalized treatment options derived from patient-specific tumour data.
Usage-based services for tumor sample screening, compound evaluation, and data analysis.
Direct sales and partnerships with healthcare institutions and biopharma companies.
Hospitals for patient samples, life science automation firms, and computational tech collaborators.
R&D focused on proprietary 3D cell culture technologies, life science process automation, and computational analysis capabilities.
Proprietary technologies integrating 3D cell culture, automation, and computational biology; expertise in patient-derived tumour screening.
Developing and operating technologies to screen patient-derived tumour samples, evaluate compound combinations, and capture functional images for decision support.
Sales-led relationships with healthcare and pharma clients through direct engagement.
Competes in the personalized oncology diagnostics space by leveraging proprietary 3D culture and automation to provide functional, patient-specific treatment insights.
Lack of actionable, evidence-based treatment decisions for cancer patients based on their specific tumour biology and response to drug combinations.
- Expand SaaS data offering - Introduce tiered API access for pharma AI teams, enabling integration of the response database into their own
- Technology validation - PreComb’s pilot studies published in Nature Communications (2024) demonstrate >70 % concordance with patient ou
No investors recorded yet.